TerminatedPhase 4

The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient

Stopped: The PI is relocating to another State/ another hospital

United States4 participantsStarted 2011-12

Plain-language summary

The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. De novo kidney transplant patients who are eligible for kidney transplant according to UNOS criteria and agree to participate in the study.
✓. Patients of both sex aged between 18 to 80 years.

What they're measuring

the combo-infection rates of the 2 cohorts of renal transplant recipients within the 12-month period after a de novo kidney transplantation

Timeframe: 12 months

Trial details

NCT IDNCT01424345

SponsorCAMC Health System

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-07

View on ClinicalTrials.gov More Kidney Transplant Immunosuppression trials